Round 2 of the Targeted Translation Research Accelerator Program

Posted: 3 October 2021
Closing: 4 November 2021

This opportunity is offered by the Commonwealth under the Targeted Translation Research Accelerator (TTRA) Program which forms part of the Medical Research Future Fund (MRFF).

The TTRA Research Projects funding can provide between $200,000 – $750,000 to help eligible organisations develop innovative preventative, diagnostic, therapeutic and/or disease management products/solutions for identified priorities associated with diabetes and cardiovascular disease.

TTRA Research Projects Round 2 Expressions of Interests must address one of the following Priority Areas:

  • Priority 1: Atherosclerosis, including cerebrovascular disease
  • Priority 2: Cardiomyopathy and heart failure
  • Priority 3: Obesity as it relates to diabetes
  • Priority 4: Mental health as it relates to diabetes
  • Priority 5: Glucose control in type 1 diabetes (T1D), type 2 diabetes (T2D), double diabetes and/or gestational diabetes mellitus (GDM)

The project term for funded TTRA Research Projects is a maximum of 24 months. Applicants will be required to provide a co-contribution to the value of 50% of the TTRA funding request to be eligible. Additional in-kind or cash contributions above this threshold will be viewed favourably.

Please review the detailed Funding Guidelines for further information about eligibility and the application process. All submissions must be made through SmartyGrants with a link provided below. The sample EOI application form provides an overview of what is required in your EOI.

Join the Zoom Information Session on Tuesday 12 October at 11:00am AEDT to learn more – register here.

For queries, please contact the TTRA team via email:


News & opinion

Member Directory